Medical versus surgical treatment for refractory or recurrent peptic ulcer by Gurusamy, KS
Cochrane Database of Systematic Reviews
Medical versus surgical treatment for refractory or recurrent
peptic ulcer (Protocol)
Gurusamy KS
Gurusamy KS.
Medical versus surgical treatment for refractory or recurrent peptic ulcer.
Cochrane Database of Systematic Reviews 2015, Issue 2. Art. No.: CD011523.
DOI: 10.1002/14651858.CD011523.
www.cochranelibrary.com
Medical versus surgical treatment for refractory or recurrent peptic ulcer (Protocol)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iMedical versus surgical treatment for refractory or recurrent peptic ulcer (Protocol)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Protocol]
Medical versus surgical treatment for refractory or recurrent
peptic ulcer
Kurinchi Selvan Gurusamy1
1Department of Surgery, Royal Free Campus, UCL Medical School, London, UK
Contact address: Kurinchi Selvan Gurusamy, Department of Surgery, Royal Free Campus, UCL Medical School, Royal Free Hospital,
Rowland Hill Street, London, NW3 2PF, UK. k.gurusamy@ucl.ac.uk.
Editorial group: Cochrane Upper GI and Pancreatic Diseases Group.
Publication status and date: New, published in Issue 2, 2015.
Citation: Gurusamy KS. Medical versus surgical treatment for refractory or recurrent peptic ulcer. Cochrane Database of Systematic
Reviews 2015, Issue 2. Art. No.: CD011523. DOI: 10.1002/14651858.CD011523.
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the benefits and harms of medical versus surgical treatment for people with recurrent or refractory peptic ulcer.
B A C K G R O U N D
Description of the condition
Peptic ulcer includes gastric and duodenal ulcers (Malfertheiner
2009). Gastric and duodenal ulcers involve defects in the mucosal
lining of the stomach and duodenum respectively. The one-year
period prevalence of physician-diagnosed peptic ulcer disease (i.e.
had peptic ulcer in a one-year period) varies between 0.12% and
1.5% (Sung 2009). The annual incidence of physician-diagnosed
peptic ulcer disease is between 0.14% and 0.19% (Sung 2009).
There has been a steady decline in the incidence and prevalence of
peptic ulcer disease (Sung 2009). Helicobacter pylori (H.pylori) in-
fection, non-steroidal anti-inflammatory drug (NSAID) use, and
smoking are the major risk factors for peptic ulcer (Huang 2002;
Kurata 1997). H. pylori induces and maintains inflammation of
the gastricmucosa leading to gastric ulcers (Peek 1997). It increases
acid secretion by increasing gastrin secretion (which in turn, in-
creases gastric acid secretion) and increases the acid secretion re-
sponse of the stomach to gastrin (Malfertheiner 2011; Peek 1997).
In addition, H. pylori also inhibits the inhibitory mechanisms that
regulate the acid secretion resulting in increased acid secretion
(Malfertheiner 2011). Increased acid in the duodenum causes gas-
tric metaplasia (replacement of duodenal epithelium with gastric
epithelium), which is the defensive reaction of the body. However,
gastric metaplasia predisposes infection of the duodenum with H.
pylori leading to duodenal ulcers (Malfertheiner 2011). Increasing
age and male gender are associated with increased incidence of
peptic ulcer (Lin 2011; Malmi 2014).
The major symptom of uncomplicated peptic ulcer is upper ab-
dominal pain, which may be associated with dyspeptic symptoms
such as fullness, bloating, early satiety, and nausea (Malfertheiner
2011). In patients with a duodenal ulcer, upper abdominal pain
typically occurs on a empty stomach or during the night and usu-
ally is relieved by eating or antacids (Malfertheiner 2011). Bleed-
ing and perforation are the two major common complications of
peptic ulcers (Hermansson 2009; Hernandez-Diaz 2013; Malmi
2014; Post 2006). The incidence rate of complications in people
without uncomplicated peptic ulcers is 4.6 per 1000 person-years
(Hernandez-Diaz 2013). The incidence of bleeding peptic ulcer
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in the general population varies between 0.27 and 1.06 per 1000
person-years, while that of perforated peptic ulcer in the general
population is 0.03 to 0.30 per 1000 person-years (Lin 2011). H.
pylori infection is a major risk factor for the development of com-
plications (Hernandez-Diaz 2013). While the incidence of peptic
ulcer complications has been decreasing in some countries such as
Sweden, Norway, and Finland (Ahsberg 2011; Hermansson 2009;
Malmi 2014; Thorsen 2013), hospitalisation due to peptic ulcer
has remained constant from 1996 in US (Manuel 2007), while the
incidence of complications of peptic ulcer has remained constant
from 1980 in Netherlands (Post 2006). Gastric outlet obstruction
is another major complication of peptic ulcer (Barksdale 2002;
Zittel 2000), but is not common in this era of H. pylori eradication
and proton pump inhibitor treatment.
Upper gastrointestinal endoscopy (oesophageo-
gastro-duodenoscopy or OGD) is the main method of diagno-
sis of peptic ulcer. Currently, OGD is indicated in people with
dyspepsia with ’alarm symptoms’ (Ford 2008; Ikenberry 2007).
Alarm symptoms include: family history of upper gastrointesti-
nal malignancy, unintended weight loss, gastrointestinal bleeding,
iron deficiency anaemia, progressive dysphagia (difficulty in swal-
lowing), persistent vomiting, palpable mass or lymphadenopathy,
and jaundice (Ikenberry 2007). In some guidelines, an older age
group (ranging from 35 to 55 years, depending upon the region)
with new onset symptoms is an indication for OGD even in the
absence of ’alarm symptoms’ (Ford 2008; Ikenberry 2007). The
main purpose of OGD is to rule out malignancy. While biopsy
of gastric ulcers suspicious of malignancy based on features such
as an associated mass lesion, elevated irregular ulcer borders, and
abnormal adjacent mucosal folds, routine biopsy in gastric ulcers
that are typical of NSAID-associated lesions, i.e. shallow flat antral
ulcer with associated erosionsmay not be necessary, although some
malignant ulcers appear benign on endoscopic visualisation ini-
tially (ASGE Standards of Practice Committee 2010). So, many
endoscopists may perform a routine biopsy of all gastric ulcers
(ASGE Standards of Practice Committee 2010). In addition to
ruling out cancers, biopsies may also be performed to rule out H.
pylori infection (ASGE Standards of Practice Committee 2010).
Many endoscopists perform a routine surveillance (follow-up) en-
doscopy to ensure that the ulcer has healed and that the ulcer is
benign (Breslin 1999). Routine biopsy is not recommended in
duodenal ulcers since duodenal ulcers are extremely unlike to be
malignant (ASGE Standards of PracticeCommittee 2010). For the
same reason, routine endoscopic surveillance is not recommended
in duodenal ulcers after resolution of symptoms with treatment
(ASGE Standards of Practice Committee 2010).
Peptic ulcers can be classified in many ways. A simple classification
is between gastric ulcers and duodenal ulcers. This is a clinically
relevant type of classification since the recommendations and en-
doscopists’ preference for biopsy and endoscopic surveillance is
different for gastric ulcers and duodenal ulcers. Various other clas-
sifications of peptic ulcer based on the location and level of acid
secretion have been proposed (Johnson 1965; Vesely 1968), but
none are currently clinically relevant based on our current under-
standing of the important role of H. pylori on the pathogenesis
of peptic ulcers. A clinically relevant method of classification of
peptic ulcer is its classification into complicated versus uncom-
plicated peptic ulcer. Major complications of peptic ulcer include
bleeding, perforation, and gastric outlet obstruction (Barksdale
2002; Hermansson 2009; Hernandez-Diaz 2013; Malmi 2014;
Post 2006; Zittel 2000). Endoscopic and medical treatments are
themainstay treatment for acute peptic ulcer bleeding (Lau 2013).
Surgery is usually reserved for unstable patients with recurrent
bleeding after endoscopic treatment (Beggs 2014; Griffiths 2013).
Currently, emergency surgery in the form of laparoscopic or open
repair of the perforated peptic ulcer is the mainstay treatment
for perforated peptic ulcers (Bertleff 2010). The treatment of pa-
tients with gastric outlet obstruction is more controversial. Elec-
tive surgery, which includes a procedure to allow the food from
the stomach to pass into the small intestine in the form of py-
loroplasty, or gastrojejunostomy (drainage procedure), which was
generally combined with another procedure to decrease the acid
secretion such as truncal vagotomy, selective vagotomy (preserv-
ing the hepatic and celiac branches of the vagus), or highly selec-
tive vagotomy (division of gastric branches of the vagus preserv-
ing Latarjet’s nerve to the pylorus) (Barksdale 2002). While en-
doscopic dilatation of the obstruction is an alternative for surgery,
the high risk of iatrogenic perforation and high recurrence rate of
peptic ulcer with endoscopic treatment meant that surgical treat-
ment was preferred over endoscopic treatment (Barksdale 2002).
However, it must be noted that the treatments for gastric outlet
obstruction evolved and were compared before the era of the pre-
proton pump inhibitor and H. pylori eradication.
Description of the intervention
H. pylori eradication achieves ulcer healing rates of more than
90% and is recommended for both gastric and duodenal ulcers
(Malfertheiner 2012). H. pylori eradication as an empirical treat-
ment (without confirmation of presence of H. pylori) in regions
with high prevalence ofH. pylori, and test-and-treat strategy (treat-
ment after confirmation of presence of H. pylori) in regions with
low prevalence of H. pylori) has been recommended for the treat-
ment of peptic ulcer (Malfertheiner 2012). The recommended
initial treatment is with a combination of proton pump inhibitor,
clarithromycin, and amoxicillin or metronidazole (triple therapy)
in regions with low resistance to clarithromycin (< 20% resistance
rate in the area) and the triple therapy alongwith bismuth (quadru-
ple therapy) in regions with high resistance to clarithromycin (>
20% resistance rate in the area) (Malfertheiner 2012). If this re-
sults in failure of eradication, bismuth-quadruple therapy or lev-
ofloxacin-triple therapy (replacement of clarithromycin with lev-
ofloxacin in the classical triple therapy) when triple therapy was
used as the initial treatment and levofloxacin-triple therapy when
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bismuth quadruple therapy was used as the initial treatment is
recommended (Malfertheiner 2012). If even this treatment fails
to eradicate H. pylori, then further treatment should be based on
antibiotic susceptibility (Malfertheiner 2012).
While the requirement for long-term proton pump inhibitors
is low in people with duodenal ulcers, long-term proton pump
inhibitors may be required for those with gastric ulcers (
Malfertheiner 2012). For refractory peptic ulcers (an ulcer that
does not heal after eight to 12 weeks after treatment or one that is
associated with complications despite treatment), further evalua-
tion of the risk factors and causes of refractory peptic ulcer includ-
ing lifestyle factors such as smoking, alcohol, NSAID use, non-
compliance with medical treatment, gastrinomas (gastrin-secret-
ing tumours), and false-negative H. pylori tests should be carried
out (Napolitano 2009). Further treatment should focus on the
treatment of the cause of the refractory ulcer, for example, smok-
ing cessation advice or alcohol cessation advice, treatment of re-
sistant H. pylori, or high-dose proton pump inhibitor or surgical
excision of gastrinomas (Napolitano 2009). Various proton pump
inhibitors for long-term treatment of refractory or recurrent ulcer
include omeprazole, lansoprazole, pantoprazole, rabeprazole, and
esomeprazole (Katz 2010). Proton pump inhibitors are generally
well tolerated, and adverse effects are relatively infrequent. The
adverse effects reported most often with proton pump inhibitors
are headache, gastrointestinal disturbances, and rash. Occasion-
ally, severe allergic reactions, anaphylactic reactions, muscle weak-
ness, reversible confusional states, mental disturbances, liver fail-
ure, kidney damage, and angina have been reported (Martindale
2011).
Surgery should be considered in patients who are intolerant or
non-compliant with medications, those at high risk for compli-
cations (for example, patients dependent on NSAIDs, ulcers that
fail to heal with adequate medical treatment), and recurrent pep-
tic ulcers despite medical treatment (Napolitano 2009). Surgery
for refractory or recurrent ulcers include truncal vagotomy and
drainage procedure (pyloroplasty or gastrojejunostomy), selective
vagotomy and drainage, highly selective vagotomy, or partial gas-
trectomy (Napolitano 2009). The complications related to trun-
cal and selective vagotomy are mortality (< 0.5%), diarrhoea, and
dumping syndrome, while themajor complication associated with
highly selective vagotomy is recurrent peptic ulcers (Lagoo 2014;
Napolitano 2009).Vagotomy is usually performedby open surgery
although case series of laparoscopic vagotomy have been reported
(Palanivelu 2006). Surgery for gastric ulcers usually involves a par-
tial gastrectomy (Napolitano 2009). Partial gastrectomy is usually
combined with vagotomy and carries a mortality (about 1%), as
well as diarrhoea, and dumping syndrome (Csendes 2009).
How the intervention might work
Medical treatments such as proton pump inhibitors work by de-
creasing acid secretion (Welage 2003). Since increased acid is con-
sidered the cause of ulcer formation, decreasing acid may result
in healing of refractory ulcers and prevention of recurrent ulcers.
Vagotomy is also aimed at decreasing the stimulation of acid se-
cretion and thus may result in healing of refractory ulcers and pre-
vention of recurrent ulcers (Napolitano 2009) as the vagus nerve
controls acid secretion. Truncal vagotomy and selective vagotomy
are combined with drainage procedures (pyloroplasty or gastro-
jejunostomy) (Napolitano 2009) because of the division of vagal
fibres that play a role in the drainage of food from stomach. Par-
tial gastrectomy is performed with the intention of decreasing the
amount of acid secreting cells (Csendes 2009).
Why it is important to do this review
Peptic ulcers cause approximately 3000 to 4500 deaths per year in
US (Peery 2012; Shaheen 2006). The estimated treatment costs is
between US $163 and US $866 per person diagnosed with pep-
tic ulcer and the estimated annual costs due to lost productivity
due to peptic ulcer is between US $943 and US $2424 per em-
ployed person in US (Barkun 2010). Overall, peptic ulcers cost
approximately US $3.5 billion annually in treatment costs and
lost productivity in US (Sandler 2002). Currently, medical man-
agement is the mainstay treatment for the treatment of uncom-
plicated chronic peptic ulcers (Malfertheiner 2011). However, it
should be noted that people with bleeding duodenal ulcers have
a lower prevalence of H. pylori (Malfertheiner 2012). Despite the
treatment of H. pylori, the recurrence rates of bleeding peptic ul-
cers vary between 0% and 37.5% (Lau 2011). Considering that
an acute episode of bleeding results in a short-term mortality of
3% (Neumann 2013) and an episode of peptic ulcer perforation
is associated with a short-term mortality of 25% to 30% (Moller
2013), it is important to prevent complications related to recur-
rent or refractory peptic ulcers. There have been recent concerns
about the risk of fractures with long-term use of proton pump
inhibitors (Yu 2011). So, it is not known whether medical or sur-
gical management is better for people with a refractory or recur-
rent peptic ulcer. There have been no systematic reviews on this
issue. This review will provide the best level of evidence on the
comparative benefits and harms of medical versus surgical man-
agement for people with a recurrent or refractory peptic ulcer and
so allow patients and the healthcare providers involved in their
care to make informed decisions or highlight the lack of evidence
on the comparative benefits and harms of medical versus surgical
management for people with recurrent or refractory peptic ulcers
and provide research recommendations.
See Appendix 1 for a glossary of terms used in the Background.
O B J E C T I V E S
To assess the benefits and harms of medical versus surgical treat-
ment for people with recurrent or refractory peptic ulcer.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs). We will in-
clude studies reported as full text, those published as abstract only,
and unpublished data. In the absence of even a single randomised
controlled trial, we will perform a meta-analysis of observational
studies clearly highlighting the selection bias in interpreting the
results. We anticipate significant selection bias in observational
studies of this comparison since there is a high possibility that
participants with low risk are subject to surgery and those at high
risk are subject to medical treatment and the effect estimates of a
meta-analysis of such observational studies can be misleading. A
single randomised controlled trial will provide a better estimate
of the effect than multiple observational studies (even if they are
showing consistent and precise results) in this particular situation.
Clearly, multiple randomised controlled trials with consistent ef-
fect estimates aremore reliable than a single randomised controlled
trial. The reason for including observational studies is to provide
an estimate of the comparative benefits for medical versus surgi-
cal management and provide information for the design of a ran-
domised controlled trial.
Types of participants
We will include adults with peptic ulcer irrespective of whether
they are gastric or duodenal ulcers, recurrent or refractory (how-
ever defined by authors), and presence or absence of previous com-
plications. We will exclude patients who have previously under-
gone surgery for peptic ulcer disease and those who are unfit for
undergoing surgery.
Types of interventions
Wewill include trials comparingmedical versus surgical treatments
for the treatment of peptic ulcer irrespective of the nature of the
medical or surgical treatments. In most instances, we anticipate
proton pump inhibitor to be the medical treatment. With regards
to surgery, we anticipate vagotomy (with drainage procedure as
appropriate), although studies may include partial gastrectomy as
the surgical treatment. We will exclude trials in which the com-
parisons solely involve comparison of different forms of medical
treatment or different forms of surgical treatment. We will accept
co-interventions, for example, the use of lifestyle modification ad-
vice, provided that they were used equally in both groups.
Types of outcome measures
Primary outcomes
1. Health-related quality of life (using any validated scale).
i) Short term (four weeks to 12 months).
ii) Medium term (one year to five years).
iii) Long term (> five years).
2. Serious adverse events (within three months of cessation of
treatment - for surgery this period refers to three months after
index surgery). We will accept the following definitions of
serious adverse events.
i) ICH-GCP International Conference on
Harmonisation - Good Clinical Practice guideline (ICH-GCP
1996): Serious adverse events defined as any untoward medical
occurrence that results in death, is life-threatening, requires
inpatient hospitalisation or prolongation of existing
hospitalisation, results in persistent or significant disability/
incapacity.
ii) Other variations of ICH-GCP classifications such as
Food and Drug Administration (FDA) classification (FDA
2006), Medicines and Healthcare products Regulatory Agency
(MHRA) classification (MHRA 2013).
Secondary outcomes
1. Adverse events (within three months of cessation of
treatment - for surgery this period refers to three months after
index surgery). We will accept all adverse events reported by the
study author irrespective of the severity of the adverse event.
2. Peptic ulcer bleeding.
i) Short term (four weeks to 12 months).
ii) Medium term (one year to five years).
iii) Long term (> five years).
3. Peptic ulcer perforation.
i) Short term (four weeks to 12 months).
ii) Medium term (four year to five years).
iii) Long term (> five years).
4. Abdominal pain.
i) Short term (four weeks to 12 months).
ii) Medium term (one year to five years).
iii) Long term (> five years).
5. Long-term mortality.
The choice of the above clinical outcomes is to assess the compar-
ative safety and clinical improvement in terms of reduced symp-
toms and complications resulting in an improvement in the health-
related quality of life between medical and surgical treatment in
patients with peptic ulcers.
Reporting of the outcomes listed here will not be an inclusion
criteria for the review.
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Search methods for identification of studies
Electronic searches
We will conduct a literature search to identify all published and
unpublished randomised controlled trials. The literature search
will identify potential studies in all languages. We will translate the
non-English language papers and fully assess them for potential
inclusion in the review as necessary.
We will search the following electronic databases for identifying
potential studies:
• Cochrane Central Register of Controlled Trials
(CENTRAL) (Appendix 2);
• MEDLINE (1966 to present) (Appendix 3);
• EMBASE (1988 to present) (Appendix 4); and
• Science Citation Index (1982 to present) (Appendix 5).
We will also conduct a search of ClinicalTrials.gov (Appendix 6)
and WHO ICTRP (World Health Organization - International
Clinical Trials Registry Platform) (Appendix 7).
Searching other resources
We will check reference lists of all primary studies and review arti-
cles for additional references.We will contact authors of identified
trials and ask them to identify other published and unpublished
studies.
Wewill search for errata or retractions from eligible trials on http://
www.ncbi.nlm.nih.gov/pubmed and report the date this was done
within the review.
Data collection and analysis
Selection of studies
Two review authors (trained research assistants or students or col-
leagues of K Gurusamy) will independently screen titles and ab-
stracts for inclusion all the potential studies we identify as a result
of the search and code them as ’retrieve’ (eligible or potentially
eligible/unclear) or ’do not retrieve’. We will retrieve the full-text
study reports and two review authors (research assistants or stu-
dents or colleagues of Dr K Gurusamy) will independently screen
the full text and identify studies for inclusion and identify and
record reasons for exclusion of the ineligible studies. We will re-
solve any disagreement through discussion or, if required, we will
consult third person (K Gurusamy). We will identify and exclude
duplicates and collate multiple reports of the same study so that
each study rather than each report is the unit of interest in the
review. We will record the selection process in sufficient detail to
complete a PRISMAflowdiagram and ’Characteristics of excluded
studies’ table.
Data extraction and management
Wewill use a standard data collection form for study characteristics
and outcome data which has been piloted on at least one study in
the review. Two review authors (research assistants or students or
colleagues of K Gurusamy) will extract study characteristics from
included studies. We will extract the following study characteris-
tics.
1. Methods: study design, total duration study and run in,
number of study centres and location, study setting,
withdrawals, date of study.
2. Participants: number (N), mean age, age range, gender,
gastric ulcer or duodenal ulcer, recurrent or refractory peptic
ulcer, and presence or absence of previous peptic ulcer-related
complications, inclusion criteria, exclusion criteria.
3. Interventions: intervention, comparison, concomitant
interventions.
4. Outcomes: primary and secondary outcomes specified and
collected, time points reported.
5. Notes: funding for trial, notable conflicts of interest of trial
authors.
Two review authors (research assistants or students or colleagues
of K Gurusamy) will independently extract outcome data form
included studies. If outcomes were reported multiple times for the
same time point, for example, short-term health-related quality
of life was reported at three months and 12 months, the later
time point (i.e. 12 months) will be chosen for data extraction.
For time-to-event outcomes, we will extract data to calculate the
natural logarithm of the hazard ratio and its standard error using
the methods suggested by Parmar et al (Parmar 1998).
All randomised participants will be included for medium out-
comes (for example, quality of life) and this will not be conditional
upon the short-term outcomes (for example, having a low or high
quality of life index at 12 months).
We will note in the ’Characteristics of included studies’ table if
outcome data were reported in an unusable way. We will resolve
disagreements by consensus or by involving a third person (K
Gurusamy). One review author (K Gurusamy) will enter the data
from the data collection form into the Review Manager file. We
will double check that the data are entered correctly by comparing
the study reports with how the data are presented in the systematic
review.
Assessment of risk of bias in included studies
Two review authors (research assistants or students or colleagues
of K Gurusamy) will independently assess risk of bias for each
study using the criteria outlined in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). Any disagreement
will be resolved by discussion or by involving a third assessor (K
Gurusamy). We will assess the risk of bias according to the follow-
ing domains.
1. Random sequence generation.
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2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We will grade each potential source of bias as high, low or un-
clear and provide a quote from the study report together with a
justification for our judgment in the ’Risk of bias’ table. We will
summarise the ’Risk of bias’ judgements across different studies for
each of the domains listed. We will consider blinding separately
for different key outcomes where necessary e.g. for unblinded out-
come assessment, risk of bias for all-cause mortality may be very
different than for a patient-reported health-related quality of life
scale). Where information on risk of bias relates to unpublished
data or correspondence with a trialist, we will note this in the ’Risk
of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assesment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations from it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Measures of treatment effect
We will analyse dichotomous data as risk ratio and continuous
data as mean difference when the outcome is reported in the same
health-related quality of life scale or standardised mean difference
when different scales are used for measuring the quality of life. We
will ensure that higher scores for continuous outcomes have the
same meaning for the particular outcome, explain the direction
to the reader and report where the directions were reversed if this
was necessary. We will calculate the rate ratio for outcomes such as
adverse events and serious adverse events, where it is possible for
the same person to developmore than one adverse event (or serious
adverse event). If the authors have calculated the rate ratio of
adverse events (or serious adverse events) in the intervention versus
control based onPoisson regression, wewill obtain the rate ratio by
the Poisson regressionmethod in preference to rate ratio calculated
based on the number of adverse events (or serious adverse events)
during a certain period.Wewill calculate the hazard ratio for time-
to-event outcomes such as time-to-first adverse event (or serious
adverse event).
We will undertake meta-analyses only where these are meaning-
ful i.e. if the treatments, participants and the underlying clinical
question are similar enough for pooling to make sense.
A common way that trialists indicate when they have skewed data
is by reporting medians and interquartile ranges. When we en-
counter this, we will note that the data are skewed and consider
the implication of this.
Where multiple trial arms are reported in a single trial, we will in-
clude only the relevant arms. If two comparisons (e.g. omeprazole
versus vagotomy and lansoprazole versus vagotomy) must be en-
tered into the same meta-analysis, we will halve the control group
to avoid double counting. The alternative way of including such
trials with multiple arms is to pool the results of the omeprazole
and lansoprazole and compare it with vagotomy. We will perform
a sensitivity analysis to determine if the results of the two methods
of dealing with multi-arm trials lead to different conclusions.
Unit of analysis issues
The unit of analysis will be individual patients with refractory
or recurrent peptic ulcer. We do not anticipate any cluster-ran-
domised trials for this comparison but if cluster-randomised trials
are identified, we will obtain the effect estimate adjusted for the
clustering effect. If this is not available, we will perform a sen-
sitivity analysis excluding the trial from the meta-analysis as the
variance of the effect estimate unadjusted for cluster effect is less
than the actual variance which is adjusted for cluster effect giving
inappropriately more weight to the cluster-randomised trial in the
meta-analysis.
Dealing with missing data
We will contact investigators or study sponsors in order to verify
key study characteristics and obtain missing numerical outcome
datawhere possible (e.g. when a study is identified as abstract only).
If we are unable to obtain the information from the investigators
or study sponsors, we will impute the mean from the median
(i.e. consider median as the mean) and standard deviation from
standard error, inter-quartile range, or P values according to the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011), but assess the impact of including such studies as indicated
in a sensitivity analysis. If we are unable to calculate the standard
deviation from standard error, inter-quartile range, or P values, we
will impute standard deviation as the highest standard deviation
in the remaining trials included in the outcome, fully aware that
this method of imputation will decrease the weight of the studies
in themeta-analysis of mean difference and shift the effect towards
no effect for standardised mean difference.
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the
trials in each analysis. If we identify substantial heterogeneity as
per Cochrane Handbook for Systematic Reviews of Interventions (>
50% to 60%), wewill explore it by pre-specified subgroup analysis.
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Assessment of reporting biases
We will attempt to contact study authors to ask them to provide
missing outcome data. Where this is not possible, and the missing
data are thought to introduce serious bias, the impact of including
such studies in the overall assessment of results will be explored by
a sensitivity analysis.
If we are able to pool more than 10 trials, we will create and
examine a funnel plot to explore possible publication biases. We
will use Egger’s test to determine the statistical significance of the
reporting bias (Egger 1997). A P value of < 0.05 will be considered
statistically significant reporting bias.
Data synthesis
We will perform the analysis using RevMan 5.3 (Review Manager
2014). We will use the Mantel Haenszel method for dichotomous
data, inverse variance method for continuous data, and generic
inverse variance for count and time-to-event data. We will use
both the fixed-effect model Demets 1987) and random-effects
model (DerSimonian 1986) for the analysis. In case of discrepancy
between the two models, we will report both results; otherwise we
will report only the results from the fixed-effect model.
’Summary of findings’ table
Wewill create a ’Summary of findings’ table using all the outcomes.
We will use the five GRADE considerations (study limitations,
consistency of effect, imprecision, indirectness and publication
bias) to assess the quality of a body of evidence as it relates to
the studies that contribute data to the meta-analyses for the pre-
specified outcomes. We will use methods and recommendations
described in Section 8.5 andChapter 12 of theCochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011) and using
GRADEpro software. We will justify all decisions to down- or up-
grade the quality of studies using footnotes and make comments
to aid reader’s understanding of the review where necessary. We
will consider whether there is any additional outcome information
that was not able to be incorporated into meta-analyses and note
this in the comments and state if it supports or contradicts the
information from the meta-analyses.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses.
1. Gastric ulcer versus duodenal ulcer.
2. Recurrent peptic ulcers versus refractory peptic ulcer.
3. Presence versus absence of previous complications
(perforation or bleeding).
4. Different surgery (truncal vagotomy versus selective
vagotomy; pyloroplasty versus gastrojejunostomy.
All the primary outcomes will be used in subgroup analysis.
We will use the formal Chi2 test for subgroup differences to test
for subgroup interactions.
Sensitivity analysis
We will perform the following sensitivity analyses defined a priori
to assess the robustness of our conclusions.
1. Excluding trials at unclear or high risk of bias (one of more
of the risk of bias domains (other than blinding of surgeon)
classified as unclear or high).
2. Excluding trials in which either mean or standard deviation
or both were imputed.
3. Excluding cluster-randomised controlled trials in which the
adjusted effect estimates are not reported.
4. Different methods of dealing with multi-arm trials (please
see Measures of treatment effect).
Reaching conclusions
We will base our conclusions only on findings from the quantita-
tive or narrative synthesis of included studies for this review. We
will avoid making recommendations for practice and our impli-
cations for research will give the reader a clear sense of where the
focus of any future research in the area should be and any remain-
ing uncertainties.
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A P P E N D I C E S
Appendix 1. Glossary of terms
Adjacent: nearby.
Anaphylactic shock: life threatening allergic reaction characterised by breathing difficulties or very low blood pressure or both.
Antral ulcers: ulcers in the antrum, the lower part of the stomach.
Antrectomy: removal of antrum, the lower part of the stomach.
Benign: non-cancerous (in this context).
Bismuth: anti-ulcer drug.
Clarithromycin, amoxicillin, metronidazole: antibiotics
Diarrhoea: frequent and loose stools
Dumping syndrome: feeling of fullness after a small meal, abdominal pain, light-headedness, and urgent requirement to pass stools.
Duodenum: first part of small intestine.
Dyspepsia: indigestion resulting in fullness, bloating, early satiety, and nausea.
Eradication: destruction.
Erosions: break only in the mucosa without a break in the deeper layers (in this context).
Endoscopy: the insertion of a tube with a camera and light through the mouth (in this context) to allow visual examination of the
oesophagus (food pipe), stomach and the upper part of the small intestines.
Gastrectomy: removal of complete stomach or part of stomach.
Gastric outlet obstruction: obstruction to the flow of food from the stomach into the small bowel.
Gastric: stomach.
Gastric mucosa: mucosa (inner lining) of the stomach.
Gastrin: hormone that increases secretion of acid in the stomach. This hormone is secreted by the gastric mucosa (inner lining of the
stomach).
Gastrointestinal: digestive.
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Gastrojejunostomy: creating a connection between stomach and the jejunum, the second part of the small intestine.
Highly selective vagotomy: division of the branches of the vagus nerve that controls the acid secretion without dividing the nerves that
control the valve like mechanism that allows food to pass from the stomach into the small bowel.
Iatrogenic: accidental or unintentional complication caused by a medical examination or treatment.
Iron deficiency anaemia: an abnormal decrease in red blood cells caused by low iron levels in the blood.
Jaundice: yellowish discolourisation of skin and white of the eye and dark urine resulting from accumulation of bile pigments (waste
products normally excreted in bile).
Lymphadenopathy: enlarged lymph glands or enlarged lymph nodes.
Malignant: cancer (in this context).
Mass: lump (in this context).
Metaplasia: replacement of cell type with another cell type which is native to another site within the body or transformation of one
tissue into another.
Mucosa: inner lining of food pipe, stomach, and bowel
Pathogenesis: mechanism of how a disease or a complication is caused.
Person-years: equivalent to 1000 persons at risk of developing peptic ulcer followed for one year or 500 persons at risk of developing
peptic ulcer followed for two years, and so on.
Proton pump inhibitor: proton pump is the pump that is responsible for secreting acid by the stomach cells. Proton pump inhibitors
are drugs that decrease the secretion of acid by blocking these pumps.
Pyloroplasty: widen the opening in the lower part of the stomach
Pylorus: the lower end of the stomach that is controlled by a valve like mechanism which allows food to pass from the stomach into
the small bowel.
Satiety: the feeling of having eaten enough or too much
Selective vagotomy: division of branches of the vagus that supply the stomach without dividing those supplying the liver.
Truncal vagotomy: division of the abdominal vagus nerve trunks which controls acid secretion and the movement of the intestines.
Appendix 2. CENTRAL search strategy
#1 MeSH descriptor: [Stomach] explode all trees
#2 stomach or gastr*
#3 MeSH descriptor: [Duodenum] explode all trees
#4 duoden*
#5 peptic*
#6 MeSH descriptor: [Esophagus] explode all trees
#7 esophag* or oesophag*
#8 MeSH descriptor: [Peptic Ulcer] explode all trees
#9 (peptic adj5 ulcer*) or (stomach adj5 ulcer*) or (duoden* adj5 ulcer*) or (gastroduoden* adj5 ulcer*)
#10 #1 or #2 or #3 or #4 or #5 or #5 or #6 or #7 or #8 or #9
#11 (recurrent or refractory or non-healing or fail*)
#12 MeSH descriptor: [Gastrectomy] explode all trees
#13 gastrectomy
#14 MeSH descriptor: [Vagotomy] explode all trees
#15 vagotomy
#16 (pyloroplasty or gastrojejunostomy or antrectomy or antrum resection or antral resection)
#17 #12 or #13 or #14 or #15 or #16
#18 #10 and #11 and #17
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Appendix 3. MEDLINE search strategy
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. exp animals/ not humans.sh.
11. 9 not 10
12. exp stomach/
13. stomach.mp.
14. gastr*.mp.
15. exp duodenum/
16. duoden*.mp.
17. peptic*.mp.
18. exp esophagus/
19. esophag*.mp.
20. oesophag*.mp.
21. exp peptic ulcer/
22. (peptic adj5 ulcer*).mp.
23. (stomach adj5 ulcer*).mp.
24. (duoden* adj5 ulcer*).mp.
25. (gastroduoden* adj5 ulcer*).mp.
26. or/12-25
27. (recurrent or refractory or non-healing or fail*).tw.
28. exp gastrectomy/
29. gastrectomy.tw.
30. exp Vagotomy/
31. vagotomy.tw.
32. pyloroplasty.tw.
33. gastrojejunostomy.tw.
34. (antrectomy or antrum resection or antral resection).mp.
35. or/28-34
36. 26 and 27 and 35
37. 11 and 36
Appendix 4. EMBASE search strategy
1. Clinical trial/
2. Randomized controlled trial/
3. Randomization/
4. Single-Blind Method/
5. Double-Blind Method/
6. Cross-Over Studies/
7. Random Allocation/
8. Placebo/
9. Randomi?ed controlled trial*.tw.
10. Rct.tw.
11. Random allocation.tw.
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12. Randomly allocated.tw.
13. Allocated randomly.tw.
14. (allocated adj2 random).tw.
15. Single blind*.tw.
16. Double blind*.tw.
17. ((treble or triple) adj blind*).tw.
18. Placebo*.tw.
19. Prospective study/
20. or/1-19
21. Case study/
22. Case report.tw.
23. Abstract report/ or letter/
24. or/21-23
25. 20 not 24
26. exp stomach/
27. stomach.mp.
28. gastr*.mp.
29. exp duodenum/
30. duoden*.mp.
31. peptic*.mp.
32. exp esophagus/
33. esophag*.mp.
34. oesophag*.mp.
35. exp peptic ulcer/
36. (peptic adj5 ulcer*).mp.
37. (stomach adj5 ulcer*).mp.
38. (duoden* adj5 ulcer*).mp.
39. (gastroduoden* adj5 ulcer*).mp.
40. or/26-39
41. (recurrent or refractory or non-healing or fail*).tw.
42. exp gastrectomy/
43. gastrectomy.tw.
44. exp vagotomy/
45. vagotomy.tw.
46. exp pyloroplasty/
47. pyloroplasty.tw.
48. exp gastrojejunostomy/
49. gastrojejunostomy.tw.
50. exp stomach antrum resection/
51. (antrectomy or antrum resection or antral resection).mp.
52. or/42-51
53. 40 and 41 and 52
54. 25 and 53
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Appendix 5. Science Citation Index search strategy
# 1 TS= (stomach or gastr* or duoden* or peptic* or esophag* or oesophag* or (peptic and ulcer*) or (stomach and ulcer*) or (duoden*
and ulcer*) or (gastroduoden* and ulcer*)
# 2 TS= (recurrent or refractory or non-healing or fail*)
# 3 TS= (gastrectomy or vagotomy or pyloroplasty or gastrojejunostomy or antrectomy or antrum resection or antral resection)
# 4 TS=(random* OR rct* OR crossover OR masked OR blind* OR placebo* OR meta-analysis OR systematic review* OR meta-
analys*)
Appendix 6. ClinicalTrials.gov search strategy
“Interventional” [STUDY-TYPES] AND ( “Phase 2” OR “Phase 3” OR “Phase 4” ) [PHASE] | “peptic ulcer” OR “duodenal ulcer”
OR “gastric ulcer” | gastrectomy OR vagotomy OR pyloroplasty OR gastrojejunostomy OR antrectomy OR “antrum resection” OR
“antral resection”
Appendix 7. WHO ICTRP search strategy
Title: gastrectomy or vagotomy or pyloroplasty or gastrojejunostomy or antrectomy or antrum resection or antral resection
Condition: peptic ulcer or gastric ulcer or duodenal ulcer
C O N T R I B U T I O N S O F A U T H O R S
Conceiving the protocol: KG
Designing the protocol: KG
Co-ordinating the protocol: KG
Designing search strategies: KG
Writing the protocol: KG
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Performing previous work that was the foundation of the current study: KG
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